"Patients with chronic conditions, such as Hepatitis C, benefit immensely when breakthrough, life-changing drugs provide a cure where none existed before. But when states are driven to create access limitations to that same drug for their Medicaid populations, we have to acknowledge something is not quite right here." Read More
“We are glad to see that the court rejected AstraZeneca’s effort to abuse the Orphan Drug Act and restrict generic competitors to Crestor,” said John Rother. “Additional competition in the prescription drug market—including generic options—is crucial to lowering prescription drug prices and providing patients with more affordable choices.” Read More
Members of the Campaign for Sustainable Rx Pricing (CSRxP) gathered on Capitol Hill to discuss market-based policy solutions to curb rising drug prices. Read More
Our new board game illustrates how pharmaceutical companies have a monopoly on the current pricing system and the different ways they keep prices high. Read More
“Voters across the country are calling for action by their elected officials to make sure patients and families don’t have to choose between filling a prescription and putting food on the table,” said CSRxP Executive Director John Rother. “The trend of rising drug prices needs to be addressed, and we expect voters will take that message – and a call for solutions – to candidates at all levels this fall.” Read More
Join the Campaign for Sustainable Rx Pricing on Capitol Hill for a discussion about market-based policy solutions to curb rising drug prices. Read More
"With this provision, policymakers are rewriting the rules to benefit pharmaceutical manufacturers for slightly tweaking their product and reintroducing it as a new 'innovation,’” CSRxP Executive Director John Rother said. Read More
"When the sticker price for 30 out of 39 of the most sold drugs goes up by more than double the rate of inflation, consumers are left holding the bag. These price increases year after year compound the problem and the whole scheme is unsustainable.” Read More
“Abusing rules and regulations to keep competitors out of the market is common in the prescription drug industry, but AstraZeneca’s latest undertaking is especially egregious." Read More
"Prescription drug costs are rising much faster than other parts of Medicare and putting ever greater financial pressure on the program and on its beneficiaries. It’s no wonder that voters are making prescription drug prices a top issue in this election." Read More
The Campaign for Sustainable Rx Pricing (CSRxP) announced its endorsement of the Creating and Restoring Equal Access to Equivalent Samples (“CREATES”) Act, a bill introduced today in the Unites States Senate. Read More
"This MEDPAC report confirms exactly what we have been saying: rising drug prices are putting a colossal burden on America’s health care system and now total nearly 20 percent of health care spending. Without market-based solutions like transparency, competition, and value, we can only expect the problem to get worse.” Read More